In a report released on February 19, Mike Kratky from Leerink Partners reiterated a Buy rating on Penumbra (PEN – Research Report), with a ...

Explore how Croom Medical and GAM are revolutionizing 3D printed tantalum implants with advanced supply chain solutions and ...

Needham & Company LLC reaffirmed their hold rating on shares of Penumbra (NYSE:PEN – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. PEN has been the topic of a ...

Penumbra, Inc. (NYSE:PEN – Get Free Report)’s stock price hit a new 52-week high during trading on Wednesday following a better than expected earnings announcement. The company traded as high as $304.

Penumbra stock climbs after Q4 earnings surpass expectations, with sales up 10.8% Y/Y. Analysts raise price targets as the ...

Q4 2024 Earnings Call Transcript February 18, 2025 Penumbra, Inc. beats earnings expectations. Reported EPS is $0.97, ...

Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ETCompany ParticipantsCecilia Furlong - Director of ...

Medical device company Penumbra (NYSE:PEN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up ...

On a per-share basis, the Alameda, California-based company said it had net income of 86 cents. Earnings, adjusted for non-recurring costs, came to 97 cents per share. The results beat Wall Street ...

Medical device company Penumbra (NYSE:PEN) will be reporting earnings tomorrow afternoon. Here’s what you need to know.

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including ...